Cycle Pharmaceuticals Ltd (“Cycle” or the “Company”), a rapidly growing pharmaceutical company focused on treatments for the underserved rare disease patient community, confirms that it has made a proposal to the Board of Directors of Vanda Pharmaceuticals, Inc. (“Vanda”) (NASDAQ: VNDA) on May 24, 2024 to acquire 100% of Vanda’s issued and outstanding shares for a cash consideration of $8.00 per Vanda share, representing a total cash consideration of $466 million.
Read the full article: Cycle Pharmaceuticals Announces All-Cash Proposal to Acquire Vanda Pharmaceuticals for $8.00 per Share //
Source: https://www.businesswire.com/news/home/20240606193221/en/Cycle-Pharmaceuticals-Announces-All-Cash-Proposal-to-Acquire-Vanda-Pharmaceuticals-for-8.00-Per-Share